iBio, Inc. (IBIO)
1.125
+0.02
(+1.35%)
USD |
NASDAQ |
Oct 02, 16:00
1.09
-0.04
(-3.11%)
After-Hours: 20:00
iBio Enterprise Value : -23.18M for Oct. 2, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 02, 2026 | -23.18M |
| October 01, 2026 | -24.02M |
| September 30, 2026 | -20.12M |
| September 29, 2026 | -20.67M |
| September 28, 2026 | -20.67M |
| September 25, 2026 | -19.56M |
| September 24, 2026 | -19.00M |
| September 23, 2026 | -16.50M |
| September 22, 2026 | -11.76M |
| September 21, 2026 | -15.66M |
| September 18, 2026 | -14.55M |
| September 17, 2026 | -16.22M |
| September 16, 2026 | -20.12M |
| September 15, 2026 | -19.56M |
| September 14, 2026 | -19.00M |
| September 11, 2026 | -18.72M |
| September 10, 2026 | -17.61M |
| September 09, 2026 | -15.66M |
| September 08, 2026 | -13.43M |
| September 04, 2026 | -12.88M |
| September 03, 2026 | -13.43M |
| September 02, 2026 | -12.88M |
| September 01, 2026 | -15.66M |
| August 31, 2026 | -15.10M |
| August 28, 2026 | -10.09M |
| Date | Value |
|---|---|
| August 27, 2026 | -7.863M |
| August 26, 2026 | -6.192M |
| August 25, 2026 | -3.964M |
| August 24, 2026 | -6.749M |
| August 21, 2026 | -6.192M |
| August 20, 2026 | -3.964M |
| August 19, 2026 | -2.850M |
| August 18, 2026 | -5.078M |
| August 17, 2026 | -5.078M |
| August 14, 2026 | -6.192M |
| August 13, 2026 | -7.863M |
| August 12, 2026 | -3.964M |
| August 11, 2026 | -3.964M |
| August 10, 2026 | -7.863M |
| August 07, 2026 | -7.306M |
| August 06, 2026 | -8.420M |
| August 05, 2026 | -7.863M |
| August 04, 2026 | -4.521M |
| August 03, 2026 | -6.749M |
| July 31, 2026 | -7.863M |
| July 30, 2026 | -8.420M |
| July 29, 2026 | -10.09M |
| July 28, 2026 | -8.420M |
| July 27, 2026 | -5.078M |
| July 24, 2026 | -6.192M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.551B |
| Alnylam Pharmaceuticals, Inc. | 29.06B |
| Savara, Inc. | 845.34M |
| Vericel Corp. | 1.987B |
| Biogen, Inc. | 39.55B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -10.60M |
| Total Expenses (Quarterly) | 10.60M |
| EPS Diluted (Quarterly) | -0.1903 |
| Earnings Yield | -40.32% |
| Normalized Earnings Yield | -37.45 |